PHOENIX, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast features Premier Biomedical, Inc. (OTCQB: BIEI) (“Company”), a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases, which has expanded into topical hemp oil pain relief products. CEO and President, William Hartman, was welcomed back to Stock Day by Everett Jolly.
Hartman started off by saying they were excited about the passage of the 2018 Farm Bill, which removes doubts surrounding the legality of hemp products.
“This opens many doors and potential sales to government agencies and the Department of Defense,” explained Hartman. “We have a unit that’s focused on selling to the military and government agencies.”
Hartman also stated that Premier Biomedical signed an agreement with a pharmacy and medical distributor and will start training their sales force early in January. He then turned to recent joint venture talks in Europe. He said Premier Biomedical, Inc. is putting that on the shelf and focusing on North America for the immediate future, with potential foreign partnerships at a later date.
“We see a whole lot more opportunity.” He added, “We are currently in discussions with two very large distributors in North America. One of these distributors specializes in convenience stores and they loved our products.”
He mentioned that the distributor to convenience stores preferred introductory products. Premier Biomedical proposed six new products, of which three were chosen. Hartman continued, “There will be a press release issued on this agreement very soon. I am excited about these products because they represent a more affordable introduction to our products.”
“We have one of the strongest topical pain relief products on the market, and we chose not to weaken them to bring the price down, but rather to make the products a little smaller. We are keeping these intro products at our Extra Strength level to provide the same effective pain relief.
”Hartman then described the other distributor as focusing on large retail facilities. He stated that Premier Biomedical will be marketing some of their new products under a new name. He said there would be a press release with the details coming very soon.
Jolly then asked Hartman to sum up 2018 accomplishments and provide an insight into 2019.
“During 2018 we continued to introduce new products, and today we have eight,” Hartman explained. “In 2019 we are going to become self-funding. That is the goal, and we are going to achieve it. We intend to get our products into the big box stores and pharmacies. We are going to become a watchword in the industry. Our products are available nationwide through our website at www.painreliefmeds.com.”
To hear the entire interview with Hartman, listen to the Stock Day podcast: https://upticknewswire.com/featured-interview-ceo-william-hartman-of-premier-biomedical-inc-otcqb-biei-12/
Contact:
William A. Hartman
President and CEO
Premier Biomedical Inc.
(724) 633-7033
w.hartman@premierbiomedical.com
www.premierbiomedical.com/
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at https://investorshangout.com/
SOURCE:
Uptick Newswire
602-441-3474
https://upticknewswire.com/